Disc Medicine (NASDAQ:IRON) Stock: Insider Kevin Bitterman Sells 5,312 Shares

Posted by Brenda Bartman on Oct 21st, 2026

Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) Director Kevin Bitterman sold 5,312 shares of the stock in a transaction on Tuesday, October 20th. The shares were sold at an average price of $79.95, for a total value of $424,694.40. Following the transaction, the director directly owned 13,257 shares of the company’s stock, valued at approximately $1,059,897.15. The trade was a 28.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Bitterman also recently made the following trade(s):

On Wednesday, October 21st, Kevin Bitterman sold 25,519 shares of Disc Medicine stock. The shares were sold at an average price of $80.23, for a total value of $2,047,389.37.
On Monday, October 19th, Kevin Bitterman sold 10,994 shares of Disc Medicine stock. The shares were sold at an average price of $79.97, for a total value of $879,190.18.
On Friday, September 11th, Kevin Bitterman sold 27,136 shares of Disc Medicine stock. The shares were sold at an average price of $70.11, for a total value of $1,902,504.96.
On Friday, September 4th, Kevin Bitterman sold 1,689 shares of Disc Medicine stock. The stock was sold at an average price of $79.96, for a total value of $135,052.44.
On Thursday, September 3rd, Kevin Bitterman sold 5,203 shares of Disc Medicine stock. The stock was sold at an average price of $79.98, for a total transaction of $416,135.94.
On Wednesday, September 2nd, Kevin Bitterman sold 49,164 shares of Disc Medicine stock. The stock was sold at an average price of $80.17, for a total transaction of $3,941,477.88.
On Tuesday, September 1st, Kevin Bitterman sold 129 shares of Disc Medicine stock. The shares were sold at an average price of $79.95, for a total transaction of $10,313.55.

Disc Medicine Price Performance

Shares of NASDAQ:IRON traded down $3.48 during trading hours on Wednesday, hitting $76.00. 4,638,911 shares of the company’s stock traded hands, compared to its average volume of 643,026. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. The company’s fifty day simple moving average is $71.53 and its two-hundred day simple moving average is $71.39. The company has a market cap of $2.92 billion, a price-to-earnings ratio of -11.55 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.71) by $0.17. As a group, equities analysts anticipate that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of Disc Medicine in a research report on Thursday, September 10th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $149.00 price target on shares of Disc Medicine in a report on Wednesday. BMO Capital Markets increased their price objective on Disc Medicine from $100.00 to $120.00 and gave the company an “outperform” rating in a research report on Monday. Wall Street Zen downgraded Disc Medicine from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Truist Financial raised their price objective on Disc Medicine from $83.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Disc Medicine has an average rating of “Moderate Buy” and an average price target of $122.70.

Get Our Latest Research Report on IRON

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in IRON. State of Wyoming purchased a new position in shares of Disc Medicine in the second quarter worth approximately $25,000. Allworth Financial LP acquired a new stake in shares of Disc Medicine during the second quarter valued at approximately $46,000. Nykredit A S acquired a new stake in shares of Disc Medicine during the second quarter valued at approximately $103,000. Quantbot Technologies LP purchased a new stake in shares of Disc Medicine in the 2nd quarter valued at approximately $153,000. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of Disc Medicine in the 1st quarter valued at approximately $207,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.